In February 2016, the UK Competition & Markets Authority (CMA) fined Actavis and other pharmaceutical companies in the context of its investigation of ‘reverse payments’ in the Paroxetine market. The investigation focused on whether payments from GlaxoSmithKline to IVAX, Generics UK, and Actavis in order to settle Paroxetine patent litigation were a violation of competition law.
Compass Lexecon provided economic advice to Actavis. Our economic analyses focused mainly on the potential competitive effects of the distribution agreements. We also assisted Actavis during its appeal of the decision to the Competition Appeal Tribunal (CAT) in April 2016.
Our team was led by Lorenzo Coppi, and included Stefano Trento, Michele Avagliano, Alyssa Lam, Rashid Muhamedrahimov, Jaime Coronado and Ferenc Peto.